WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

Inclusion Criteria:

• Participant is an adult (according to the age of majority as defined by local regulations)
• Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
• Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
• Informed consent has been obtained from the participant or legally authorized representative, as per local regulations

Exclusion Criteria:

-Participant has a prior or current diagnosis of haematological malignancy

Male and Female adult participants who are diagnosed with solid tumour cancers (at any anatomical location) and at any stage of the disease who have undergone an NGS test.

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing